- Home
- CBAN vs YMAB Comparison
CBAN vs YMAB Comparison
Compare CBAN & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBAN
- YMAB
- Stock Information
- Founded
- CBAN 1975
- YMAB 2015
- Country
- CBAN United States
- YMAB United States
- Employees
- CBAN N/A
- YMAB N/A
- Industry
- CBAN Major Banks
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- CBAN Finance
- YMAB Health Care
- Exchange
- CBAN Nasdaq
- YMAB Nasdaq
- Market Cap
- CBAN 285.4M
- YMAB 270.5M
- IPO Year
- CBAN 1998
- YMAB 2018
- Fundamental
- Price
- CBAN $16.77
- YMAB $5.12
- Analyst Decision
- CBAN
- YMAB Buy
- Analyst Count
- CBAN 0
- YMAB 11
- Target Price
- CBAN N/A
- YMAB $18.73
- AVG Volume (30 Days)
- CBAN 86.4K
- YMAB 374.3K
- Earning Date
- CBAN 04-23-2025
- YMAB 03-04-2025
- Dividend Yield
- CBAN 2.73%
- YMAB N/A
- EPS Growth
- CBAN 9.88
- YMAB N/A
- EPS
- CBAN 1.36
- YMAB N/A
- Revenue
- CBAN $112,401,000.00
- YMAB $87,685,000.00
- Revenue This Year
- CBAN $14.25
- YMAB $20.07
- Revenue Next Year
- CBAN $6.28
- YMAB $8.76
- P/E Ratio
- CBAN $12.38
- YMAB N/A
- Revenue Growth
- CBAN 1.93
- YMAB 3.38
- 52 Week Low
- CBAN $10.33
- YMAB $4.25
- 52 Week High
- CBAN $18.49
- YMAB $17.78
- Technical
- Relative Strength Index (RSI)
- CBAN 57.88
- YMAB 47.05
- Support Level
- CBAN $16.11
- YMAB $4.75
- Resistance Level
- CBAN $16.88
- YMAB $5.32
- Average True Range (ATR)
- CBAN 0.36
- YMAB 0.29
- MACD
- CBAN 0.08
- YMAB 0.09
- Stochastic Oscillator
- CBAN 95.49
- YMAB 79.44
About CBAN Colony Bankcorp Inc.
Colony Bankcorp Inc is a bank holding company. The bank provides a broad range of banking services to its retail and commercial customers. Its product line includes loans to small and medium-sized businesses, residential and commercial construction and land development loans, commercial real estate loans, agri-business and production loans, residential mortgage loans, consumer loans, and a variety of demand, savings, and time deposit products. The company's segments include the Banking Division, Retail Mortgage Division and small business specialty lending divisions. It generates maximum revenue from the Banking Division.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.